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Abstract
An UPLC-MS/MS method was developed for the determination of serotonin (5-HT), dopamine (DA), their phase I
metabolites 5-HIAA, DOPAC and HVA, and their sulfate and glucuronide conjugates in human brain microdialysis samples
obtained from two patients with acute brain injuries, ventricular cerebrospinal fluid (CSF) samples obtained from four
patients with obstructive hydrocephalus, and a lumbar CSF sample pooled mainly from patients undergoing spinal
anesthesia in preparation for orthopedic surgery. The method was validated by determining the limits of detection and
quantification, linearity, repeatability and specificity. The direct method enabled the analysis of the intact phase II
metabolites of 5-HT and DA, without hydrolysis of the conjugates. The method also enabled the analysis of the regioisomers
of the conjugates, and several intact glucuronide and sulfate conjugates were identified and quantified for the first time in
the human brain microdialysis and CSF samples. We were able to show the presence of 5-HIAA sulfate, and that dopamine-
3-O-sulfate predominates over dopamine-4-O-sulfate in the human brain. The quantitative results suggest that sulfonation
is a more important phase II metabolism pathway than glucuronidation in the human brain.
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Introduction
Dopamine (DA) and serotonin (5-HT) are monoamine neuro-
transmitters in the human brain that are involved in several
physiological processes. 5-HT is involved in the regulation of
several physiological functions, including the sleep-wake cycles,
body temperature, blood pressure, perception of pain, hormonal
functions of the hypothalamus and psychological functions, such as
depression and anxiety [1,2]. The functions of DA have been
linked to Parkinson’s disease, schizophrenia, depression and the
regulation of motoric movements [3–5]. The levels of both these
neurotransmitters are regulated in the brain by reuptake and
metabolism. Both DA and 5-HT are metabolized by monoamine
oxidase (MAO) to the phase I metabolites 3,4-dihydroxyphenyla-
cetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA),
respectively. DOPAC is further metabolized to homovanillic acid
(HVA) by catechol-O-methyltrasferase (COMT) (Figure 1). Both
DA and 5-HT, and their respective metabolites, can undergo
conjugation with glucuronic acid or sulfonate mediated by
catalysis with UDP-glucuronosyltransferases (UGTs) and sulfo-
transferases (SULTs), respectively. The UGTs are a family of
enzymes that catalyze the glucuronidation of various compounds,
and thereby have an important role in the intestinal, hepatic and
renal metabolism and detoxification of a large number of
xenobiotic and endogenous compounds [6,7]. The expression of
UGTs is tissue-specific. Many UGTs are expressed in the liver, but
UGTs are also expressed in other organs and some of the UGTs
are expressed only or mainly in extra-hepatic tissues, such as the
gastrointestinal tract, the olfactory mucosa, adipose tissue and the
kidneys. Small amounts of UGT mRNA have also been found in
several other tissues, including the heart, adrenal gland, trachea
and brain [7–10]. In the human brain, which is the focus of this
study, low mRNA levels of the UGTs 1A4, 1A5, 1A6, 2A1, 2A2,
2A3, 2B7, 2B11 and 2B17 have been reported. However, the
findings were not consistent, which was probably due to the low
number of donors and inter-individual variability [8,10]. In
addition, some of the earlier studies on UGTs expression in
different organs [6,7] were carried out using less quantitative
methods that are more prone to errors. Recent studies used
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quantitative real-time PCR (qRT-PCR), in which the detected
mRNA levels of the UGTs in the brain samples were either not
found or if so were barely above the detection limits. Nevertheless,
5-HT has been shown to be a substrate for at least one human
UGT, UGT1A6, and very low 5-HT glucuronidation activity was
also reported for UGT2B7 [6,11,12]. DA has been shown to be
conjugated mainly by UGT1A10, and very low activities were
reported for UGTs 1A6, 2A1, 2A3, 2B7, 2B11 and 2B17 [13].
Another family of enzymes, the SULTs, catalyze the sulfonation
of different compounds, and are equally important in the
metabolic conjugation of xenobiotics and endogenous compounds.
There are 13 different human sulfotransferases that can be divided
into three families, SULT1, SULT2, and SULT4. Similar to that
of the UGTs, the expression of SULTs is tissue-specific. The liver
is the most abundant site for most SULTs expression, although the
intestine, lung, kidney and brain also express SULTs [14,15].
SULT 1A3, which is the SULT enzyme that is mainly responsible
for monoamine metabolism, in addition to SULT 1A1, 2A1, 1E1
and 4A1, have also been shown to be expressed in the human
brain [14,16].
The phase I metabolism of monoamine neurotransmitters in the
human central nervous system is relatively well documented. 5-
HT, DA and their phase I metabolites have previously been
determined in human lumbar and ventricular cerebrospinal fluid
(CSF), and in human brain tissue in several studies [17–23].
However, the phase II metabolism in the central nervous system
has been less studied, which is partly due to the lack of
commercially available standard compounds, i.e. neurotransmitter
glucuronides and sulfates. Therefore, such conjugates in the
human cerebrospinal fluid (CSF) or brain samples have mostly
been analyzed after acid or enzymatic hydrolysis of the conjugates
[24–28]. Sulfate conjugates of DA, 5-HT, epinephrine and
norepinephrine [27–30] and glucuronide conjugates of DA and
norepinephrine [27] have been identified after hydrolysis of the
conjugates in CSF samples. Some studies have reported the
detection of conjugated DA, DOPAC, HVA and 5-HT in human
CSF, but do not specify the type of conjugate [26,31–33].
Moreover, conjugated monoamine neurotransmitter metabolites
have been found in human brain tissue samples. Glucuronide
conjugates of HVA, DOPAC, 5-HIAA, and 4-hydroxy-3-me-
thoxy-phenylglycol (a metabolite of norepinephrine) and DOPAC
sulfate were identified after hydrolysis in a tissue sample taken
from the human caudate nucleus [24]. Furthermore, conjugated
DA has been found in the human caudate nucleus and
hypothalamus, although the specific conjugate type was not
identified [34]. DA and 5-HT were shown to be sulfonated also
in vitro studies using phenol sulfotransferase preparate isolated from
human brain tissue homogenates [35–37].
The conjugates of monoamine neurotransmitter in human CSF
or brain samples have been analyzed in all the earlier studies by
using indirect methods employing either acid or enzymatic
hydrolysis of the conjugates. Indirect methods, however, do not
provide identification of the conjugates with absolute certainty,
since the hydrolysis step is prone to errors even by employing
specific enzymes such as b-glucuronidase or sulfatase. In addition,
the site of conjugation cannot be determined by indirect methods,
and the reliability of the quantification of the conjugates is
questionable, since the hydrolysis might not be complete. Only
recently, methods have been developed for the analysis of intact
phase II metabolites of monoamine neurotransmitters and
neurosteroids in rat and mouse brain [38–41]. Intact glucuronide
conjugates of both 5-HT and DA, and sulfate conjugates of their
phase I metabolites 5-HIAA, DOPAC and HVA were recently
found in rat and mouse brain microdialysates in our laboratory by
using a direct analysis method [40,41].
Microdialysis, which has been largely used in the analysis of
neurotransmitters and their metabolites in the central nervous
system of laboratory animals, mainly in rats and mice, provides a
more reliable method to examine the physiological state of the
brain than the methods employing post mortem brain tissue
samples. Microdialysis of the human brain has been used to
monitor neurointensive care patients with subarachnoid hemor-
rhage, traumatic brain injury, thromboembolic stroke or epilepsy
[42–45]. Monoamine neurotransmitters and their phase I
metabolites in human brain microdialysates have been analyzed
in only a few studies [43,44,46–50].
Until now, no intact conjugated phase II metabolites of
neurotransmitters have been analyzed in human brain samples
and therefore the aim of this work was to study the existence of
monoamine neurotransmitter metabolites, especially glucuronides
and sulphates, in human brain microdialysates and CSF. For this
purpose, we developed a sensitive and selective ultra-performance
liquid chromatographic - mass spectrometric (UPLC-MS/MS)
method, which provides direct and thus more reliable analysis of
sulfate and glucuronide conjugates than the earlier methods
employing hydrolysis of the conjugates.
Results and Discussion
UPLC-MS/MS Method Development and Validation
The UPLC-MS/MS method developed in this work for the
analysis of DA and 5-HT and their phase I and phase II
metabolites (Table S1) in human brain microdialysis and CSF
samples was based on the HPLC-MS/MS method presented
earlier by our group [40,41]. Pentafluorophenyl columns were
used in both studies, but the column is narrower (2.1 mm) and the
particle size smaller (1.9 mm) in the UPLC method than in the
HPLC method (4 mm, 3 mm). The advantage of using a narrow
UPLC column instead of a normal size HPLC column was the
possibility to reduce the injection volume from 100 mL to 15 mL,
without reducing sensitivity. Relatively high injection volumes
were necessary in order to achieve sufficient sensitivity levels.
The use of a more hydrophilic pentafluorophenylpropyl column
instead of a commonly used C-18 column provided good retention
and separation of the metabolites from each other and also from
the inorganic salts in the Ringer’s solution. The salts were directed
to waste using column switching before the elution of the analytes,
in order to avoid contamination of the ion source, thus ensuring
long-term robust analysis. The UPLC method provided high
separation resolution for the analytes, and also separation of the
regioisomers DA-3-O-sulfate (DA-3-O-S) and DA-4-O-sulfate
(DA-4-O-S), in addition to HVA-O-glucuronide (HVA-O-G)
Figure 1. Main metabolic routes of serotonin and dopamine to
their phase I metabolites.
doi:10.1371/journal.pone.0068007.g001
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and HVA-COO-glucuronide (HVA-COO-G) (Figures S1 and S2).
Electrospray ionization (ESI) in the positive ion mode provided
high ionization efficiency for 5-HT, DA, 5-HT-glucuronide (5-
HT-G), 5-HT-sulfate (5-HT-S), and DA-glucuronide (DA-G),
whereas the negative ion mode provided better ionization
efficiency for DA-3-O-S and DA-4-O-S, as well as for DOPAC,
HVA, 5-HIAA, and their glucuronide and sulfate conjugates. The
positive and negative ion ESI mass spectra showed abundant
[M+H]+ and [M–H]2 ions, which were chosen for the precursor
ions. The MS and MS/MS spectra have been presented and
discussed earlier [41]. The identification of the neurotransmitters
and their metabolites was based on the comparison of the
retention times and relative abundances of 2–3 selected reaction
monitoring (SRM) transitions (Table S1) of each analyte between
the reference standards diluted in Ringer’s solution and the
authentic samples. The variation of the intensity ratios of the
monitored product ions was less than 15%, and the variation of
the retention times was less than 1.5% in all positive identifica-
tions. The samples were analyzed in two runs using the same
chromatographic gradient but monitoring different SRM transi-
tions in order to maximize sensitivity and selectivity.
The quantitative UPLC-MS/MS method was validated for the
following parameters: specificity, limit of detection (LOD) with a
signal-to-noise ratio (S/N) of 3, limit of quantification (LOQ) with
a S/N of at least 10 and at most a 20% deviation from the linearity
curve, linearity, and repeatability using standards diluted in
Ringer’s solution (Table 1). LODs were determined by analyzing
low concentration spiked standard samples and blank samples
(n = 5). The measured low concentration samples resulted in
signals of which S/N values varied between 3 and 10. The LODs
were estimated by calculating the concentration of the respective
analytes that would give a S/N-ratio of 3. The specificity of the
method was tested and verified by comparing blank and spiked
Ringer’s solution samples. The SRM chromatograms of the blank
samples (Ringer’s solution) showed no analyte peaks, which
indicated good specificity and no memory effects. The LODs for
5-HT, DA, 5-HT-G, 5-HT-S and DA-G analyzed in the positive
ion mode were 0.02–0.40 nM (0.3–6 fmol injected on the
column). The LODs for DA-3-O- and DA-4-O-S, HVA, DOPAC,
5-HIAA, and their glucuronides and sulfates in the negative ion
mode varied between 0.3 and 25 nM (4.5–375 fmol injected on
the column). The LODs for DA and 5-HT and their metabolites
were at the same level as described earlier [39–41,51,52]. The
correlation coefficients (r2) for the calibration curves that were
measured by using an external standard method were .0.996,
which indicated good linearity of the method. The within-day
repeatability of the method was studied at concentration levels of
10 and/or 100 nM (Table 1). The relative standard deviations (%
rsd) were below 10%, indicating good repeatability. Concerning
the microdialysis samples, the recoveries of the neurotransmitters
and their phase I and II metabolites across the microdialysis
membrane were not determined, but the typical in vivo recovery
for small molecules (glucose, lactate, pyruvate, glutamate) in
microdialysis has been reported to be 65–70% [53]. The
concentration ratios between the analytes are expected to be
similar to those in the brain fluid, since the permeability of the
analytes through the microdialysis membrane is not selective.
Neurotransmitters and their Metabolites Measured in the
Human Brain Microdialysis and CSF Samples
The microdialysis samples from two patients (patients 1 and 2)
suffering from acute brain injury (subarachnoid hemorrhage) were
analyzed as such. 5-HT was identified at low concentrations
(,1 nM) in the microdialysis samples from patient 2, but not from
patient 1. DA was not detected in any of the samples (Table 2).
The LODs for 5-HT and DA were 0.2 nM respectively (Table 1),
which suggests that the concentrations of 5-HT (patient 1) and DA
(both patients) were below their respective LODs. The most
abundant metabolite of DA was HVA (150–2000 nM), but HVA-
O-glucuronide (12–15 nM) was also identified in the samples
obtained from patient 1. DA-3-O-S was clearly identified in both
patients (patient 1:330–630 nM, patient 2:2.5–3.5 nM), but DA-4-
O-S was not found in any of the samples. The most abundant
metabolites of 5-HT were 5-HIAA (90–110 nM) and 5-HIAA-S
(380–550 nM), but low concentrations of 5-HT-G (0.45–0.8 nM)
were also identified in the samples from patient 1 (Figure 2).
Low concentrations of 5-HT (1.2 nM or less) were detected in
three of the ventricular CSF samples similar to those found in the
brain microdialysis samples. In comparison DA was not detected
in any of the samples. The most abundant metabolite of DA was
also HVA, but the concentrations of which were about one order
of magnitude higher (600–4200 nM) in the ventricular samples
than in the lumbar sample (120 nM). DA-3-O-S (9.4–18 nM) was
detected in all the samples but DA-4-O-S only in one sample
(2.0 nM). The most abundant metabolites of 5-HT were 5-HIAA
(35–1400 nM) and 5-HIAA-S (86–390 nM), which corresponded
to those found for the microdialysis samples. 5-HT-S was detected
at a low concentration only in the lumbar CSF sample, but 5-HT-
G that was detected in the microdialysis samples was not detected
in any of the CSF samples (Figure 3).
The findings and concentrations of the neurotransmitters and
their metabolites are in relatively good agreement between the
microdialysis and the CSF samples. The main phase I metabolites
of DA and 5-HT were HVA and 5-HIAA, respectively. These
results are consistent with earlier studies of their concentrations in
human brain tissue [18–22] and human CSF samples
[17,18,29,54]. Earlier studies reported that DOPAC was detected
in human brain tissue samples [19,21,22,34], in microdialysis
samples [46,48] and CSF samples [17,18,29], but it was not
detected in this study. This may be due to insufficient sensitivity of
the method or to fast degradation of DA and DOPAC during the
sample storage, as reported earlier by several groups [28,40,55].
The intact phase II metabolites, 5-HIAA-S, DA-3-O-S, DA-4-
O-S, 5-HT-S, 5-HT-G, and HVA-O-G were detected in human
brain or CSF for the first time in this work. There are earlier
reports of HVA-G, DOPAC-G, 5-HIAA-G and DOPAC-S in
tissue samples of the human brain [24], and DA-G, 5-HT-G, 5-
HT-S [27] and DA-S [27–30,33,54] have been found in human
CSF. However, all these metabolites were detected after a
hydrolysis step, which makes their determinations less reliable
than our direct method of detecting intact conjugates. In addition
5-HIAA-S, which has not been detected in the human brain or
CSF in earlier works, was now found at relatively high
concentrations. The concentrations of 5-HIAA-S were around
3–5 times higher than those of free 5-HIAA in the human
microdialysis and lumbar CSF samples, and about half the
concentration of free 5-HIAA in the ventricular CSF samples.
DA-3-O-S was clearly detected in all the samples and DA-4-O-
S in only one sample, which indicated that the DA-3-O-S
regioisomer predominates in the human brain. These results are in
accordance with the observation that DA-3-O-S predominates in
human plasma at concentrations of about ten-fold higher than
those of the regioisomer DA-4-O-S [56]. It has been shown that
the isoenzyme SULT1A3, which is also found in the human brain
[14], is regioselective and strongly favors the formation of DA-3-
O-S over DA-4-O-S [57]. Sulfonation of 5-HT was less favored
than sulfonation of DA, as 5-HT-S was only detected in the
lumbar CSF sample at a low concentration.
Human Brain Neurotransmitter Metabolites
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Two glucuronides, 5-HT-G and HVA-O-G, were detected
for the first time in human brain samples. However, the
glucuronides were only found in the microdialysis samples of
patient 1 at low concentrations, and no glucuronides were
detected in the CSF samples. The amount of HVA-O-G was
less than 1% of the amount of free HVA. This result may be
considered to be in line with the reported 5-HT glucuronidation
of UGT1A6 (Figure S3 and ref. 11) and the barely detectable
expression of this enzyme in the brain [6,8]. However, this
result is not in line with another study that reported on 23
tissue types [10]. HVA can be glucuronidated both at the
phenolic hydroxyl and the carboxylic acid group sites. Our
screening experiment reveals that UGT1A10 is the most active
human UGT in the formation of HVA-O-glucuronide, whereas
UGT2A1 is the most active for the conjugation of HVA at the
–COOH-group (Fig. S4). These glucuronidation results are
interesting and new, but they also clearly show that glucur-
onidation is not a major biotransformation pathway for 5-HT
and HVA in the human brain. In general, the results in Table 2
suggest that conjugation with sulfonate is the major phase II
metabolism pathway in the human brain.
Conclusions
The microdialyis sampling and the developed UPLC-MS/MS-
analysis method require minimal sample pretreatment, and
provide sensitive and selective analysis of intact phase II
metabolites of neurotransmitters in the human brain. In this
study, intact phase II metabolites of 5-HT and DA were analyzed
in the human brain samples without hydrolysis of the conjugates,
and several intact glucuronides and sulfates were unambiguously
identified and quantified in human brain microdialysis and CSF
samples. 5-HIAA-S was found for the first time in human brain. As
the direct method provides analysis of regioisomers of conjugates,
we were able to show that DA-3-O-S predominates over DA-4-O-
S in the human brain. The quantitative results show that
sulfonation is a significant phase II metabolism pathway in the
human brain.
Further studies including samples from a larger group of
patients would be needed to study interindividual differences in
the amounts of conjugated neurotransmitters versus the
concentrations of the parent compounds. The metabolic
turnover of the compounds should also be studied. The role
of the conjugation of neurotransmitter in the brain is still
unknown. It is also unknown whether the conjugates possess
neurotoxic or neuroprotective properties, are pharmacologically
active or not, or even if they are hydrolysed in vivo, and
additional experiments are needed in order to study the
pharmacological impact of conjugated and especially sulfonated
neurotransmitters on different brain functions.
Materials and Methods
Reagents and Standards
3,4-dihydroxyphenethylamine hydrochloride (DA) and 3-me-
thoxy-4-hydroxyphenylacetic acid (HVA) were purchased from
Sigma-Aldrich (St. Louis, MO). 5-hydroxytryptamine (5-HT), 3,4-
dihydroxyphenylacetic acid (DOPAC) and 5-Hydroxyindole-3-
acetic acid (5-HIAA) and formic acid were purchased from Sigma-
Aldrich (Steinheim, Germany). Acetonitrile (ACN) was purchased
from Rathburn (Walkerburn, Scotland). Ringer’s solution, used for
dilution of the standards, contained 147 mM NaCl (Akzo Nobel,
Table 1. Validation results for all the compounds analyzed.
Linearity LOD LOQ Repeatability Repeatability
range S/N =3 S/N $10 Accuracy 10 nM, n=6 100 nM, n=6
Compound nM r2 nM nM % rsd % rsd %
DA 0.5–25 0.997 0.2 0.5 90–120 6.0 nm
DA-G 0.5–50 0.998 0.1 0.5 90–110 4.3 nm
DA-3-S 1–50 0.997 0.3 1 91–116 5.1 0.6
50-1000 0.998 93–115
DA-4-S 1–1000 0.998 0.3 1 91–112 5.7 1.5
5-HT 1–25 0.996 0.2 1 89–112 1.8 nm
5-HT-G 0.25–25 0.997 0.02 0.25 96–103 2.5 nm
5-HT-S 1–100 0.999 0.4 1 94–107 2.6 nm
DOPAC 50–1000 0.998 10 50 95–110 nm
DOPAC-G 25–1000 0.996 2.5 25 93–113 nm 2.0
DOPAC-S 25–1000 0.998 4.3 25 95–110 nm nm
HVA 100–1000 0.999 25 100 98–102 nm 7.0
250–5000 0.999 95–120
HVA-OH-G 5–100 0.999 1.0 5 92–111 4.9 2.9
HVA-S 5–500 0.999 1.4 5 95–118 nm nm
5-HIAA 25–1000 0.998 6.4 25 91–106 nm 4.0
250–3500 0.999 95–103
5-HIAA-G 5–500 0.998 1.0 5 86–116 7.2 3.2
5-HIAA-S 10–1000 0.999 5.0 10 96–113 nm 10.0
nm=not measured.
doi:10.1371/journal.pone.0068007.t001
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Denmark), 1.2 mM CaCl2 (J.T.Bakers, Deventer, The Nether-
lands), 2.7 mM KCl (Sigma-Aldrich, Steinheim, Germany),
1.0 mM MgCl2 (Riedel-de-Haehn AG, Seelze, Germany), and
0.04 mM ascorbic acid (University Pharmacy, Helsinki, Finland).
Uridine 59-diphosphoglucuronic acid tri-ammonium salt
(UDPGA), were purchased from Sigma–Aldrich (St. Louis, MO,
USA).
Table 2. Findings in the human brain microdialysis and the human cerebrospinal fluid samples.
Microdialysis samples Cerebrospinal fluid samples
Patient 1 Patient 2 Ventricular Lumbar
Compound Sample 1 Sample 2 Sample 1 Sample 2 Patient 3 Patient 4 Patient 5 Patient 6 Pooled
5-HT – – 0.52a 0.54a 0.84a – 0.70a 1.2 –
5-HT-S – – – – – – – – 0.63a
5-HT-G 0.45 0.80 – – – – – – –
5-HIAA 90 110 90 100 1400 340 220 540 35
5-HIAA-S 450 550 520 380 370 170 96 390 86
5-HIAA-G – – – – – – – – –
DA – – – – – – – – –
DA-3-O-S 330 630 3.5 2.5 10 18 14 9.4 12
DA-4-O-S – – – – – – 2.0 – –
DA-G – – – – – – – – –
HVA 1100 2000 280 150 4200 601 2200 2200 120
HVA-S – – – – – – – – –
HVA-O-G 15 12 – – – – – – –
DOPAC – – – – – – – – –
DOPAC-S – – – – – – – – –
DOPAC-G – – – – – – – – –
All concentrations are in nM.
The microdialysis samples (patients n = 2) were analyzed as singles. Each of the CSF samples (four ventricular CSF samples (patients 1–4), one lumbar CSF sample pooled
from several patients were analyzed in triplicate (concentrations shown are the mean concentrations). – not detected, a,LOQ, concentration estimated by extrapolation
of the linearity curve.
doi:10.1371/journal.pone.0068007.t002
Figure 2. Findings in the human brain microdialysis samples. SRM ion chromatograms of A: standards (1 nM 5-HT and 5-HT-G, 5 nM DA-3-O-
S and HVA-O-G, 100 nM HVA, 5-HIAA and 5-HIAA-S); B: a blank sample (Ringer’s solution); C: a human brain microdialysis sample from patient 1; D: a
human brain microdialysis sample from patient 2.
doi:10.1371/journal.pone.0068007.g002
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Synthesis of Phase II Metabolites
The synthesis of the phase II metabolites of 5-HT, DA and their
phase I metabolites, which were used as reference standards in this
study, had been done earlier in our laboratory and has been
described in detail elsewhere [40,41].
Microdialysis Samples
The human brain microdialysis samples were obtained from the
Neurointensive care unit of the Uppsala University Hospital, in
collaboration with the University of Uppsala, from two patients
with acute brain injuries (subarachnoid hemorrhage). 172 fractions
were collected from patient 1. The sample volume was about 5–
10 mL per fraction, collected in a time-resolved mode from day 1–
8. 132 fractions of similar volume were collected from patient 2 in
a time-resolved mode from day 1–6. Both patients were female,
aged 71 and 50 years, had a decreased level of consciousness, were
intubated and received artificial ventilation. Propofol sedation was
used initially. Intracerebral microdialysis sampling was initiated, in
conjunction with the insertion of an ICP monitoring device,
through microdialysis catheters inserted via a bur hole placed 1–
2 cm anterior to the coronal suture. Care was taken to insert the
microdialysis probe obliquely in macroscopically nonlesioned
cortex by using atraumatic techniques aiming at an intracortical
positioning of the microdialysis membrane. Microdialysis catheters
with a membrane length of 10 mm and a 20-kDa nominal
molecular weight cut-off polyamide membrane (70 Brain Micro-
dialysis Catheter; M Dialysis AB, Solna, Sweden) were used. The
outflow hydrostatic pressure of the perfusion system was set at the
zero mid-cranial reference level by taping the collecting vials next
to the bandage on the patient’s head. Perfusion of the catheters
was performed using artificial CSF (Perfusion Fluid CNS, M
Dialysis AB), containing NaCl 147 mM, CaCl2 1.7 mM, KCl
2.7 mM, MgCl 0.85 mM, total chloride contents 153.8 mM,
osmolarity 305 mOsm/kg), delivered at a rate of 0.3 mL/min by
using a microdialysis pump (106 MD Pump, M Dialysis AB). At
least 2 hours passed between insertion of the probe and the start of
Figure 3. Findings in the human CSF samples. SRM ion chromatograms of A: standards (0.5 nM 5-HT and 5-HT-S, 10 nM DA-4- and 3-O-S and
100 nM HVA, 5-HIAA and 5-HIAA-S); B: a blank sample (Ringer’s solution); C-F: ventricular cerebrospinal fluid samples from patients 3–6; G: lumbar
cerebrospinal fluid sample pooled from several patients.
doi:10.1371/journal.pone.0068007.g003
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sampling to allow for normalization of changes due to probe
insertion. The samples were frozen on dry ice and stored at -70uC,
and were thawed and pooled just before the analysis. The samples
were injected as such and analyzed as single replicates. The
sampling was approved by the Regional Research Ethics
Committee at Uppsala University, and a written informed consent
was obtained from the patient or the patient’s closest relative, in
case the patient was unconscious.
Cerebrospinal Fluid Samples
The human ventricular cerebrospinal fluid samples (n = 4) were
obtained from the Department of Neurosurgery at Helsinki
University Central Hospital. The samples were obtained by
ventriculostomy, and approximately 10 mL of ventricular CSF
was obtained from each patient. The patients were being treated
in the neurosurgical intensive care unit for obstructive hydro-
cephalus. The patients were a 82-year old male with a cerebellar
infarct (patient 3), a 46-year old female with subarachnoid
hemorrhage (patient 4), a 35-year old male with a cerebellar
infarct (patient 5), and a 55-year old female with a tumor (patient
6). Since the samples were taken from CSF waste accumulated
during therapeutic CSF drainage (appr. 200 ml/day/patient),
which was going to be discarded as a part of the clinical routine,
no informed consent from the patients or the next of kin was
deemed necessary.
A pool of CSF from 200 subjects from Sweden (all without a
neurologic or psychiatric disease, most who underwent lumbar
puncture for non-diagnostic reasons and who had normal CSF
clinical laboratory values; over 90% were undergoing spinal
anesthesia in preparation for orthopedic surgery (e.g. limbs as
knees and hips) [58]. Ages ranged from 16 to 65 years with a
median of 44 years; 50:50 female:male. These samples were
collected on ice and cells were removed by centrifugation [59].
Approval for the conduct of this study was obtained from the
Institutional Review Board in accordance with federal regulations.
Approval for the conduct of this study was obtained from the local
Ethics Committee at Uppsala University as well as Go¨teborg
University, Sweden. The participants provided their written
informed consent to participate in this study. A written informed
consent was obtained from the next of kin, caretaker, or guardian
on the behalf of participants that were not able to sign the
informed consent themselves. The ethics committees approved of
this consent procedure.
All cerebrospinal fluid samples were kept at -70uC until analysis.
After thawing, the samples were ultrafiltered (Millipore Amicon
Ultrafree-MC, 30 000 NMWL) by centrifugation (12 000 g,
15 min), and the filtrate was injected as such. All the CSF samples
were analyzed in triplicate.
UGT Experiments
All UGTs had been expressed in our laboratory as described
earlier [12,60,61]. Glucuronidation activities were determined
with 2 mM 5-HT or HVA, and 5 mM UDPGA, 50 mM
phosphate buffer pH 7.4 and 10 mM MgCl2 and the samples
were incubated at 37uC for 60 min. All UGTs were screened as
duplicates, except for 5-HT as a substrate for 2B15, which was
analyzed as a single sample and showed no activity. Negative
control samples, including all the reaction assay components, with
the exception of UDPGA, were also analyzed.
UPLC-MS/MS
The UPLC-MS/MS system used in the analysis consisted of an
Aquity UPLC (Waters, Milford, MA) coupled to an Agilent 6410
triple quadrupole (Agilent technologies, Santa Clara, CA). The
column used was a pentafluorophenyl column (Thermo Scientific
Gold PFP Hypersil, 2,1 x 150 mm, 1.9 mm). The eluents used
were A: aqueous 0.1% formic acid and B: acetonitrile +0.1%
formic acid. Different linear gradients were used for the
microdialysis and cerebrospinal fluid samples. The gradient used
in the analysis of the microdialysis samples was: B 3% 0–1.5 min,
15% 12 min, 65% 13 -13.2 min, 3% 13.5 min, followed by an
equilibration of 11.5 min with a total run time of 25 minutes. The
flow rate was 0.3 mL/min, and the column oven temperature was
kept at 30uC. The injection volume was 15 ml. The gradient used
for the analysis of the cerebrospinal fluid samples was similar: B
3% 0–1.5 min, 15% 12 min, 85% 13 -13.2 min, 3% 13.5 min,
followed by an equilibration of 11.5 min with a total run time of
25 minutes. The flow from the UPLC was directed to waste for the
first minutes of the gradient (Table S1) to avoid contamination of
the ion source by the salts of the Ringer’s solution or the
cerebrospinal fluid.
An Agilent 6410 triple-quadrupole mass spectrometer (Agilent
Technologies, Santa Clara, CA) with an electrospray ion source
was used in the quantitative analyses of the brain samples.
Nitrogen (Parker Balston N2-22 nitrogen generator, Parker
Hannifin Corporation, Haverhill) was used as the nebulizer
(40 psi), curtain (12 L/min, 350uC), and collision gas. The
fragmentor voltages and collision energies were optimized for
each compound, and Agilent MassHunter software versions
B.04.00 (quantitative data analysis) and B.03.01 (qualitative data
analysis) were used for data acquisition and processing. The
compound-specific mass spectrometric parameters had been
optimized earlier [41].
As the analysis method contained several analytes, which
require either positive or negative ionization, two separate runs
were needed for each sample. The compounds followed in each
run, in addition to the SRM transitions and ionization modes are
shown in Table S1. The method was validated in terms of
linearity, limit of detection (LOD), limit of quantification (LOQ)
and repeatability for each compound.
Supporting Information
Figure S1 SRM ion chromatograms of the monoamine
neurotransmitters and their metabolites. (Run 1, see
Table S1).
(TIF)
Figure S2 SRM ion chromatograms of the monoamine
neurotransmitters and their metabolites. (Run 2, see
Table S1).
(TIF)
Figure S3 5-HT glucuronidation by different UGT
enzymes. The actual and normalized glucuronidation rates (with
respect to the expression level of UGT1A10) of the enzymes are
shown. These data represent the means of duplicate samples. See
material and methods for details.
(EMF)
Figure S4 HVA glucuronidation at the phenolic and the
carboxylic acid groups by different UGT enzymes. The
actual and normalized glucuronidation rates with respect to the
expression level of UGT1A10 of the enzymes are shown. See
material and methods for details.
(EMF)
Table S1 Time segments of the chromatographic runs,
SRM transitions and ionisation modes of the analytes.
(XLSX)
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